B. Riley Securities resumed coverage on KORU Medical Systems with a new price target
$KRMD
Medical/Dental Instruments
Health Care
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $4.50 | Overweight → Neutral | Piper Sandler |
| 7/25/2024 | $4.00 | Buy | B. Riley Securities |
| 9/7/2023 | $4.00 | Buy | Lake Street |
| 9/7/2023 | $4.50 | Buy | B. Riley Securities |
| 11/10/2022 | $3.00 → $4.00 | Hold → Buy | Canaccord Genuity |
| 11/10/2022 | $3.00 → $3.50 | Neutral → Overweight | Piper Sandler |
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 million, a 23% increase over the prior year period; Full year 2024 net revenues of $33.6 million, an 18% increase over the prior year Fourth quarter 2024 Core business (Domestic and International) net revenues of $8.2 million, a
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced preliminary unaudited revenues for the second quarter 2023 and provided business, outlook and executive updates. The Company reported total net revenues for the second quarter 2023 of approximately $6.9 million, representing growth of approximately 6% compared to the prior year period. Domestic Core revenues increased approximately 8%, International Core revenues increased approximatel
Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 million, a 23% increase over the prior year period; Full year 2024 net revenues of $33.6 million, an 18% increase over the prior year Fourth quarter 2024 Core business (Domestic and International) net revenues of $8.2 million, a
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)